Contact Details
- Phone
- +64 3 479 8524
- michelle.glass@otago.ac.nz
- Position
- Professor
- Qualifications
- PhD BSc
- Research summary
- Cannabinoids, neurodegenerative diseases, Huntington’s disease, G-protein coupled receptors
Research
Michelle Glass is a molecular pharmacologist who joined the Department of Pharmacology and Toxicology at the University of Otago as Head of Department in 2018, moving here from the University of Auckland where she worked for 18 years.
She returned to the department where her working career began 23 years ago. Professor Glass’ first role after graduating with a PhD from the Department of Pharmacology at the University of Auckland in 1995 was as an Assistant Lecturer in the Department of Pharmacology at the University of Otago.
Her initial stint at Otago was brief as she took up a fellowship in the United States the following year. She worked as a postdoctoral Fellow in the Laboratory of Cellular and Molecular Regulation at the National Institute of Mental Health in Bethesda, Maryland for 18 months before moving on to work as a Visiting Fellow in the Laboratory of Cell Biology at the National Institute of Deafness and Other Communications Disorders in Rockville, Maryland. She returned to New Zealand in 2000 and took up a role as a Lecturer within the Department of Pharmacology at the University of Auckland.
Professor Glass’ research focuses on the expression, function and molecular pharmacology of the cannabinoid receptors and their potential role in treatment of neurodegenerative diseases. Her recent research interests have extended to identifying the mechanism by which synthetic cannabinoids are resulting in high levels of toxicity in the community and advising on the development of clinical trials for medicinal cannabis products.
Currently, Professor Glass is a member of the Medical Cannabis Research Collaborative (NZ), which aims to ensure robust clinical research of medical cannabis products in New Zealand is undertaken. It will also set informal standards for the development and testing of medical cannabis products, as well as increasing understanding and the base of evidence for or against the use of medical cannabis products in specific clinical conditions. Her contributions to the field have been acknowledged by an early career award from the International Cannabinoid Research Society in 2009 and by election to President of this society.
She acknowledges it is an interesting time with change potentially in the wind with so many countries legalising cannabis.
“I think it’s important that the science keeps up with the public debate.”
Read more in Otago Bulletin:
Synthetic cannabis under spotlight for new Pharmacology head
Publications
Patel, M., Ganeshan, D., Horgan, I., Partington, H., & Glass, M. (2026). AB-MDMSBA: Not a synthetic cannabinoid receptor agonist. Pharmacology Research & Perspectives, 14(3), e70278. doi: 10.1002/prp2.70278 Journal - Research Article
Alexander, S. P. H., Bennett, K. A., Brown, A. J., Glass, M., Gloriam, D. E., Hanson, J., … Davenport, A. P. (2026). International Union of Basic and Clinical Pharmacology xxx: Applying an objective evaluation to the status of Class A orphan G protein-coupled receptors. Pharmacological Reviews. Advance online publication. doi: 10.1016/j.pharmr.2026.100141 Journal - Research Article
Alexander, P. H., Davenport, A. P., Kelly, E., Gibb, A. J., Mathie, A. A., Peach, C. J., … Garelja, M. L., … Glass, M., … Hay, D. L., … Zaidman, N. (2025). The concise guide to Pharmacology 2025/26: G protein-coupled receptors. British Journal of Pharmacology, 182, S24-S151. doi: 10.1111/bph.70230 Journal - Research Article
Oyagawa, C. R. M., Woodhouse, B., Wood, K. C., Glass, M., & Grimsey, N. L. (2025). Insights into cannabinoid receptor 2 (CB2) anterograde trafficking and pharmacological chaperoning. Cellular & Molecular Life Sciences. Advance online publication. doi: 10.1007/s00018-025-05961-w Journal - Research Article
Glass, M., Khalajiassadi, N., Chen, S., Ganeshan, D., Partington, H., & Finlay, D. B. (2025). Development of a cell membrane conformational cannabinoid CB(1) receptor biosensor for the detection of synthetic cannabinoids. ACS Sensors. Advance online publication. doi: 10.1021/acssensors.4c03589 Journal - Research Article
2026
Journal - Research Article
Patel, M., Ganeshan, D., Horgan, I., Partington, H., & Glass, M. (2026). AB-MDMSBA: Not a synthetic cannabinoid receptor agonist. Pharmacology Research & Perspectives, 14(3), e70278. doi: 10.1002/prp2.70278
Alexander, S. P. H., Bennett, K. A., Brown, A. J., Glass, M., Gloriam, D. E., Hanson, J., … Davenport, A. P. (2026). International Union of Basic and Clinical Pharmacology xxx: Applying an objective evaluation to the status of Class A orphan G protein-coupled receptors. Pharmacological Reviews. Advance online publication. doi: 10.1016/j.pharmr.2026.100141
2025
Chapter in Book - Research
Ehrlich, B., Patel, M., Zheng, X., & Glass, M. (2025). Canonical cannabinoid receptors. In Current topics in behavioral neurosciences. Berlin, Germany: Springer. doi: 10.1007/7854_2024_556
Journal - Research Article
Alexander, P. H., Davenport, A. P., Kelly, E., Gibb, A. J., Mathie, A. A., Peach, C. J., … Garelja, M. L., … Glass, M., … Hay, D. L., … Zaidman, N. (2025). The concise guide to Pharmacology 2025/26: G protein-coupled receptors. British Journal of Pharmacology, 182, S24-S151. doi: 10.1111/bph.70230
Oyagawa, C. R. M., Woodhouse, B., Wood, K. C., Glass, M., & Grimsey, N. L. (2025). Insights into cannabinoid receptor 2 (CB2) anterograde trafficking and pharmacological chaperoning. Cellular & Molecular Life Sciences. Advance online publication. doi: 10.1007/s00018-025-05961-w
Glass, M., Khalajiassadi, N., Chen, S., Ganeshan, D., Partington, H., & Finlay, D. B. (2025). Development of a cell membrane conformational cannabinoid CB(1) receptor biosensor for the detection of synthetic cannabinoids. ACS Sensors. Advance online publication. doi: 10.1021/acssensors.4c03589
Komal, K., Hanton, L. R., Glass, M., & Das, S. C. (2025). Influence of different amino acids on the aerosolization, stability and cytotoxicity of spray-dried cannabidiol dry powder for inhalation. Pharmaceutics, 17(9), 1120. doi: 10.3390/pharmaceutics17091120
Komal, K., Chen, S., Hanton, L. R., Glass, M., & Das, S. C. (2025). Preparation and in vitro characterization of inhalable cannabidiol dry powder for treating chronic obstructive pulmonary disease. International Journal of Pharmaceutics, 682, 125892. doi: 10.1016/j.ijpharm.2025.125892
Yang, L., Finlay, D., Glass, M., & Duffull, S. (2025). Development of a heuristic machine analogy method for model simplification with an application to a large-scale model of Gi/Gs signaling. CPT: Pharmacometrics & Systems Pharmacology. Advance online publication. doi: 10.1002/psp4.70029
Humphrey, B., Glass, M., Hill, J., Osborne, A. J., Stouffer, D. B., Noble, A., … Chen, S., & Nelson, X. J. (2025). The effect of delta-9 tetrahydrocannabinol and methamphetamine on sustained attention in the jumping spider (Trite planiceps). Journal of Comparative Psychology, 139(2), 134-146. doi: 10.1037/com0000396
Zheng, X., Ehrlich, B., Finlay, D., & Glass, M. (2025). No evidence for endocannabinoid-induced G protein subtype selectivity at human and rodent cannabinoid CB1 receptors. Cannabis & Cannabinoid Research, 10(3), 425-435. doi: 10.1089/can.2024.0133
Conference Contribution - Published proceedings: Abstract
Henderson, M., & Glass, M. (2025). Development of a fluorescence-based assay to screen novel synthetic cathinones. In A. Banstola (Ed.), Proceedings of the 41st International Australasian Winter Conference on Brain Research (AWCBR). 11.26, (pp. 67). Retrieved from https://www.awcbr.org
2024
Journal - Research Article
Green, H. M., & Glass, M. (2024). Could positive allosteric modulators of the cannabinoid CB1 receptor be efficacious and safe for the treatment of chronic pain? Current Opinion in Pharmacology, 79, 102495. doi: 10.1016/j.coph.2024.102495
Thomsen, L. R., Glass, M., & Rosengren, R. J. (2024). The impact of piperazine and antipsychotic co-exposures and CB1 blockade on the effects elicited by AMB-FUBINACA, a synthetic cannabinoid, in mice. European Journal of Pharmacology, 979, 176844. doi: 10.1016/j.ejphar.2024.176844
Green, H. M., Manning, J. J., Greig, I. R., Ross, R. A., Finlay, D. B., & Glass, M. (2024). Positive allosteric modulation of the cannabinoid CB1 receptor potentiates endocannabinoid signalling and changes ERK1/2 phosphorylation kinetics. British Journal of Pharmacology, 181, 3642-3662. doi: 10.1111/bph.16433
Manning, J. J., Finlay, D. B., & Glass, M. (2024). GPCR kinase subtype requirements for arrestin-2 and -3 translocation to the cannabinoid CB1 receptor and the consequences on G protein signalling. Biochemical Pharmacology, 224, 116190. doi: 10.1016/j.bcp.2024.116190
Patel, M., Zheng, X., Akinfiresoye, L. R., Prioleau, C., Walker, T. D., Glass, M., & Marusich, J. A. (2024). Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists. European Journal of Pharmacology, 971, 176549. doi: 10.1016/j.ejphar.2024.176549
Ryalls, B., Patel, M., Sparkes, E., Banister, S. D., Finlay, D. B., & Glass, M. (2024). Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB1 receptor. Biochemical Pharmacology, 222, 116052. doi: 10.1016/j.bcp.2024.116052
Green, H. M., Fellner, D. M. J., Finlay, D. B., Furkert, D. P., & Glass, M. (2024). Determination of the cannabinoid CB1 receptor's positive allosteric modulator binding site through mutagenesis studies. Pharmaceuticals, 17, 154. doi: 10.3390/ph17020154
Yang, L., Finlay, D. B., Green, H. M., Zhu, X., Glass, M., & Duffull, S. (2024). A quantitative pharmacology model for cannabinoid CB1 receptor mediated by Gi/Gs protein competition. British Journal of Pharmacology, 181(8), 1324-1340. doi: 10.1111/bph.16293
Green, H. M., Yang, L., Zhu, X., Finlay, D. B., Duffull, S. B., & Glass, M. (2024). Insight into the mechanism of action of ORG27569 at the cannabinoid type one receptor utilising a unified mathematical model. Naunyn-Schmiedeberg's Archives of Pharmacology, 397, 5105-5118. doi: 10.1007/s00210-023-02923-6
Conference Contribution - Published proceedings: Full paper
Komal, K., Glass, M., & Das, S. C. (2024). Kaempferol can increase aerosolization and decrease the cytotoxicity of inhaled cannabidiol. Proceedings of the 35th Drug Delivery to the Lungs (DDL) Conference. 35, (pp. 185-188). doi: 10.60565/cjpx-1k63
Conference Contribution - Poster Presentation (not in published proceedings)
Komal, K., Glass, M., & Das, S. C. (2024, August-September). Impact of amino acids on aerosolization and cytotoxicity of inhalable cannabidiol. Poster session presented at the 18th New Zealand Medical Sciences Congress (MedSci), Queenstown, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Komal, K., Shah, R. M., Glass, M., & Das, S. (2024, November). Leucine enhances the aerosolization of inhalable cannabidiol dry powder developed by spray freeze drying. Verbal presentation at the School of Pharmacy Research Symposium, Dunedin, New Zealand.
Liddle, I., de la Harpe, S., Rajapakse, C., Glass, M., Tyndall, J., & Vernall, A. (2024, November). Allosteric modulators for the cannabinoid receptor 2. Verbal presentation at the School of Pharmacy Research Symposium, Dunedin, New Zealand.
2023
Chapter in Book - Research
Lu, D., & Glass, M. (2023). Org27569, the allosteric modulators and the cannabinoid receptor 1 (CB1). In V. B. Patel, V. R. Preedy & C. R. Martin (Eds.), Neurobiology and physiology of the endocannabinoid system. (pp. 365-377). London, UK: Academic Press. doi: 10.1016/B978-0-323-90877-1.00015-2
Journal - Research Article
Patel, M., Grimsey, N. L., Banister, S. D., Finlay, D. B., & Glass, M. (2023). Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB2 receptor. Pharmacology Research & Perspectives, 11, e01157. doi: 10.1002/prp2.1157
Haney, M., Vallée, M., Fabre, S., Collins Reed, S., Zanese, M., Campistron, G., … Finlay, D. B., … Glass, M., … Piazza, P. V. (2023). Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: Phase 1 and phase 2a randomized trials. Nature Medicine, 29, 1487-1499. doi: 10.1038/s41591-023-02381-w
Yang, L., Zhu, X., Finlay, D. B., Green, H., Glass, M., & Duffull, S. B. (2023). A kinetic model for positive allosteric modulator (PAM)-antagonists for the type 1 cannabinoid receptor (CB1). British Journal of Pharmacology, 180, 2661-2676. doi: 10.1111/bph.16158
Finlay, D. B., Mackie, W., Webb, H. D. J., Thomsen, L. R., Nimick, M., Rosengren, R. J., … Glass, M., & Wiley, J. L. (2023). The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolism. Pharmacology Biochemistry & Behavior, 23, 173530. doi: 10.1016/j.pbb.2023.173530
Webb, H. D. J., Finlay, D. B., Chen, S., Vernall, A. J., Sparkes, E., Banister, S. D., Rosengren, R. J., & Glass, M. (2023). Characterisation of AMB-FUBINACA metabolism and CB1-mediated activity of its acid metabolite. Forensic Toxicology, 41, 114-125. doi: 10.1007/s11419-022-00649-3
Manning, J. J., Rawcliffe, G., Finlay, D. B., & Glass, M. (2023). Cannabinoid type-1 receptor arrestin subtype-selectivity and phosphorylation dependence. British Journal of Pharmacology, 180, 369-382. doi: 10.1111/bph.15973
Conference Contribution - Published proceedings: Abstract
Komal, K., Chen, S., Glass, M., & Das, S. C. (2023). Inhalable cannabidiol dry powder for treating chronic obstructive pulmonary disease. Proceedings of the New Zealand Controlled Release Society (NZCRS) Symposium. Retrieved from http://nzcrs.org.nz/#/home
Ryalls, B. E., Finlay, D. B., Hughes, S., & Glass, M. (2023). Developing a relevant model of cannabinoid receptor (CB1) signalling using human stem cell-derived neurons. Proceedings of the Graduate Research Student Symposium. (pp. 24). Retrieved from https://www.otago.ac.nz/graduate-research
Kuepper, N., Lee, K. L., & Glass, M. (2023). Cannabinoids influence insulin secretion in a mouse pancreatic β-cell line. In T. Milne, M. Anwar, L. Burga, H. Harcombe, M. Garelja, A. Middleton, D. C. Ribeiro, N. Fleming, K. Ogbuehi & A. Bahn (Eds.), Proceedings of the 268th Otago Medical School Research Society (OMSRS) Meeting: Masters/Honours/Postgraduate Diploma Student Speaker Awards. Dunedin, New Zealand: OMSRS. Retrieved from https://ourarchive.otago.ac.nz/handle/10523/12839
Thomsen, L. R., Finlay, D. B., Glass, M., & Rosengren, R. J. (2023). Clinically relevant drugs modulate the effect of AMB-FUBINACA in male and female mice. In T. Milne, M. Anwar, L. Burga, H. Harcombe, M. Garelja, A. Middleton, D. C. Ribeiro, N. Fleming, K. Ogbuehi & A. Bahn (Eds.), Proceedings of the 267th Otago Medical School Research Society (OMSRS) Meeting: PhD Student Speaker Awards. Dunedin, New Zealand: OMSRS. Retrieved from https://ourarchive.otago.ac.nz/handle/10523/12839
Ryalls, B., Finlay, D., Hughes, S., & Glass, M. (2023). Developing a relevant model of cannabinoid receptor signalling using human iPSC-derived neurons. In K.-L. Horne (Ed.), Proceedings of the 39th International Australasian Winter Conference on Brain Research (AWCBR). (pp. 45). Retrieved from https://www.awcbr.org
Other Research Output
Glass, M. (2023, September). Synthetic cannabinoids: What we know and what we need to know. UOC Research Seminar Series, University of Otago, Christchurch, New Zealand. [Research Presentation].
2022
Journal - Research Article
Green, H. M., Finlay, D. B., Ross, R. A., Greig, I. R., Duffull, S. B., & Glass, M. (2022). In vitro characterization of 6-methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1 H-indole (ZCZ011) at the type 1 cannabinoid receptor: Allosteric agonist or allosteric modulator? ACS Pharmacology & Translational Science, 5, 1279-1291. doi: 10.1021/acsptsci.2c00160
Sparkes, E., Boyd, R., Chen, S., Markham, J. W., Luo, J. L., Foyzun, T., … Glass, M., … Banister, S. D. (2022). Synthesis and pharmacological evaluation of newly detected synthetic cannabinoid receptor agonists AB-4CN-BUTICA, MMB-4CN-BUTINACA, MDMB-4F-BUTICA, MDMB-4F-BUTINACA and their analogs. Frontiers in Psychiatry, 13, 1010501. doi: 10.3389/fpsyt.2022.1010501
Kevin, R. C., Mirlohi, S., Manning, J. J., Boyd, R., Cairns, E. A., Ametovski, A., … Glass, M., … Banister, S. D. (2022). Putative synthetic cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and their analogues are T-type calcium channel (CaV3) inhibitors. ACS Chemical Neuroscience, 13, 1395-1409. doi: 10.1021/acschemneuro.1c00822
Markham, J., Sparkes, E., Boyd, R., Chen, S., Manning, J. J., Finlay, D., … Glass, M., … Banister, S. D. (2022). Defining steric requirements at CB1 and CB2 cannabinoid receptors using synthetic cannabinoid receptor agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and their analogues. ACS Chemical Neuroscience, 13, 1281-1295. doi: 10.1021/acschemneuro.2c00034
Finlay, D. B., Nguyen, T., Gamage, T. F., Chen, S., Barrus, D. G., Patel, P. R., … Glass, M. (2022). Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG-018. Pharmacology Research & Perspectives, 10, e00901. doi: 10.1002/prp2.901
Nguyen, T., Gamage, T. F., Finlay, D. B., Decker, A. M., Langston, T. L., Barrus, D., Glass, M., … Zhang, Y. (2022). Development of 3-(4-chlorophenyl)-1-(phenethyl)urea analogues as allosteric modulators of the cannabinoid type-1 receptor: RTICBM-189 is brain penetrant and attenuates reinstatement of cocaine-seeking behavior. Journal of Medicinal Chemistry, 65, 257-270. doi: 10.1021/acs.jmedchem.1c01432
Shirazi, R. S., Vyssotski, M., Lagutin, K., Thompson, D., MacDonald, C., Luscombe, V., Glass, M., … Gowing, E. K., … Clarkson, A. N. (2022). Neuroprotective activity of new Δ3-N-acylethanolamines in a focal ischemia stroke model. Lipids, 57, 17-31. doi: 10.1002/lipd.12326
Sparkes, E., Cairns, E. A., Kevin, R. C., Lai, F., Grafinger, K. E., Chen, S., … Glass, M., … Banister, S. D. (2022). Structure-activity relationships of valine-, tert-leucine-, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA. RSC Medicinal Chemistry, 13, 156-174. doi: 10.1039/D1MD00242B
Journal - Research Other
Liddle, I., Glass, M., Tyndall, J. D. A., & Vernall, A. J. (2022). Covalent cannabinoid receptor ligands: Structural insight and selectivity challenges. RSC Medicinal Chemistry, 13, 497-510. doi: 10.1039/D2MD00006G
Daldegan-Bueno, D., Maia, L. O., Glass, M., Jutras-Aswad, D., & Fischer, B. (2022). Co-exposure of cannabinoids with amphetamines and biological, behavioural and health outcomes: A scoping review of animal and human studies. Psychopharmacology, 239, 1211-1230. doi: 10.1007/s00213-021-05960-2
Conference Contribution - Published proceedings: Abstract
Liddle, I., Glass, M., Tyndall, J. D. A., & Vernall, A. J. (2022). Covalent chromenopyrazole chemical tools for the cannabinoid type 2 receptor. In L. Wilson, H. Harcombe, P. Jayakaran, L. Burga, J. Antony, K. Morgaine, M. Garelja, A. Middleton, M. Anwar & T. Milne (Eds.), Proceedings of the 263rd Otago Medical School Research Society (OMSRS) Meeting: PhD Student Speaker Awards. Dunedin, New Zealand: OMSRS. Retrieved from https://ourarchive.otago.ac.nz/handle/10523/12839
Conference Contribution - Poster Presentation (not in published proceedings)
Komal, K., Glass, M., & Das, S. C. (2022, November). Prospects of cannabidiol inhalation. Poster session presented at the New Zealand Controlled Release Society (NZCRS) Symposium, Auckland, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Green, H. M., Finlay, D. B., & Glass, M. (2022, September). Positive allosteric modulation of the type 1 cannabinoid receptor potentiates endocannabinoid signalling and changes ERK1/2 phosphorylation kinetics. Verbal presentation at the Postgraduate & Early Career Researchers Committee (PERC) & Division of Health Sciences Early & Mid-Career Researcher (EMCR) Joint Research Symposium, Dunedin, New Zealand.
Rawcliffe, G., Grabenheinrich, T., Dass, P., Flanagan, J., & Glass, M. (2022, August-September). Investigating the signalling of an atypical group of receptors: GPCR bigrams. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) NZ Annual Scientific Meeting, Queenstown, New Zealand.
Green, H. M., Finlay, D. B., & Glass, M. (2022, August-September). Positive allosteric modulation of type 1 cannabinoid receptor potentiates endocannabinoid signalling and changes ERK1/2 phosphorylation kinetics. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) NZ Annual Scientific Meeting, Queenstown, New Zealand.
Ehrlich, B. E., Patel, M., Banister, S. D., Finlay, D. B., & Glass, M. (2022, August-September). Investigating G protein vs β-arrestin bias of late-generation synthetic cannabinoids at the CB1 receptor. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) NZ Annual Scientific Meeting, Queenstown, New Zealand.
Patel, M., Matti, C., Grimsey, N. L., Legler, D. F., Finlay, D. B., & Glass, M. (2022, August-September). Delineating the interactions between the cannabinoid CB2 receptor and its regulatory effectors: β-arrestin 2 and G protein-coupled receptor kinases. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) NZ Annual Scientific Meeting, Queenstown, New Zealand.
Glass, M. (2022, March). What is medicinal cannabis? Plenary presentation at the New Zealand Pain Society (NZPS) Annual Scientific Meeting, [Online].
2021
Journal - Research Article
Patel, M., Matti, C., Grimsey, N. L., Legler, D. F., Javitch, J. A., Finlay, D. B., & Glass, M. (2021). Delineating the interactions between the cannabinoid CB2 receptor and its regulatory effectors: β‐arrestins and GPCR kinases. British Journal of Pharmacology, 179, 2223-2239. doi: 10.1111/bph.15748
Ametovski, A., Cairns, E. A., Grafinger, K. E., Cannaert, A., Deventer, M. H., Chen, S., … Glass, M., … Banister, S. D. (2021). NNL-3: A synthetic intermediate or a new class of hydroxybenzotriazole esters with cannabinoid receptor activity? ACS Chemical Neuroscience, 12, 4020-4036. doi: 10.1021/acschemneuro.1c00348
Yang, L., Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2021). Exploring group size for statistical analysis of real-time signalling experiments. British Journal of Pharmacology, 178, 3997-4004. doi: 10.1111/bph.15572
Manning, J. J., Green, H. M., Glass, M., & Finlay, D. B. (2021). Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias. Neuropharmacology, 193, 108611. doi: 10.1016/j.neuropharm.2021.108611
Nguyen, T., Gamage, T. F., Decker, A. M., Finlay, D. B., Langston, T. L., Barrus, D., Glass, M., … Zhang, Y. (2021). Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids. Bioorganic & Medicinal Chemistry, 41, 116215. doi: 10.1016/j.bmc.2021.116215
Patel, M., Finlay, D. B., & Glass, M. (2021). Biased agonism at the cannabinoid receptors: Evidence from synthetic cannabinoid receptor agonists. Cellular Signaling, 78, 109865. doi: 10.1016/j.cellsig.2020.109865
Singh, S., Liddle, I., Macdonald, C., Tyndall, J. D. A., Glass, M., & Vernall, A. (2021). Development of chromenopyrazole-based selective cannabinoid 2 receptor agonists. Australian Journal of Chemistry, 74, 433-442. doi: 10.1071/CH20263
Robson, H., Braund, R., Glass, M., Ashton, J., & Tatley, M. (2021). Synthetic cannabis: Adverse events reported to the New Zealand Pharmacovigilance Centre. Clinical Toxicology, 59(6), 472-479. doi: 10.1080/15563650.2020.1828592
Mielnik, C. A., Sugamori, K. S., Finlay, D. B., Thorpe, H. H. A., Schapira, M., Sivananthan, N., … Glass, M., … Ross, R. A. (2021). A novel allosteric modulator of the cannabinoid CB1 receptor ameliorates hyperdopaminergia endophenotypes in rodent models. Neuropsychopharmacology, 46, 413-422. doi: 10.1038/s41386-020-00876-5
Journal - Research Other
Daldegan-Bueno, D., Maia, L. O., Glass, M., Jutras-Aswad, D., & Fischer, B. (2021). Co-exposure of cocaine and cannabinoids and its association with select biological, behavioural and health outcomes: A systematic scoping review of multi-disciplinary studies. European Neuropsychopharmacology, 51, 106-131. doi: 10.1016/j.euroneuro.2021.06.002
Conference Contribution - Published proceedings: Abstract
Glass, M. (2021). Synthetic cannabinoids: Not just man-made cannabis! Proceedings of the 16th Congress of the Federation of Asian & Oceanic Biochemists & Molecular Biologists (FAOBMB). (pp. 186). Retrieved from https://www.faobmb2021.org
Fellner, D. M. J., Glass, M., & Furkert, D. P. (2021). Essential dynamics of distinct ligand-bound CB1 cannabinoid receptor conformations: Implications for agonist bias. Proceedings of the 16th Congress of the Federation of Asian & Oceanic Biochemists & Molecular Biologists (FAOBMB). (pp. 66). Retrieved from https://www.faobmb2021.org
Yang, L., Finlay, D., Zhu, X., Green, H., Glass, M., & Duffull, S. (2021). A quantitative pharmacology model for CB1 receptor mediate by Gi Gs protein competition. Proceedings of the Twenty-Ninth Annual Meeting of the Population Approach Group in Europe (PAGE). Retrieved from https://page-meeting.org
Zhu, X., Finlay, D. B., Manning, J. J., Glass, M., & Duffull, S. B. (2021). Positive allosteric modulators: A challenge for development of QSP models. Proceedings of the Twenty-Ninth Annual Meeting of the Population Approach Group in Europe (PAGE). Retrieved from https://page-meeting.org
Naqash, A., Kemp, R., Glass, M., & Wise, L. (2021). Control of immune cell function by IL-10 proteins derived from viruses. Proceedings of the University of Otago Student Research Symposium: Te Wānaka Rakahau: Ākoka. (pp. 46). [Abstract]
Khalajiassadi, N., Finlay, D., Patel, M., & Glass, M. (2021). ABM300, a new negative allosteric modulator of the CB1 cannabinoid receptor, exhibits a similar mechanism of action as ORG27569. New Zealand Medical Journal, 134(1537), (pp. 117). Retrieved from https://www.nzma.org.nz/journal
2020
Journal - Research Article
Ametovski, A., Macdonald, C., Manning, J. J., Syed Haneef, S. A., Santiago, M., Martin, L., … Glass, M., & Banister, S. D. (2020). Exploring stereochemical and conformational requirements at cannabinoid receptors for synthetic cannabinoids relating to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA. ACS Chemical Neuroscience, 11, 3672-3682. doi: 10.1021/acschemneuro.0c00591
Narayan, P., Reid, S., Scotter, E. L., McGregor, A. L., Mehrabi, N. F., Singh-Bains, M. K., Glass, M., … Dragunow, M. (2020). Inconsistencies in histone acetylation patterns among different HD model systems and HD post-mortem brains. Neurobiology of Disease, 146, 105092. doi: 10.1016/j.nbd.2020.105092
Van den Berg, M., John, M., Black, M., Semprini, A., Oldfield, K., Glass, M., & Braithwaite, I. (2020). Cannabis-based medicinal products in arthritis, a painful conundrum. New Zealand Medical Journal, 133(1515), 35-45. Retrieved from https://www.nzma.org.nz/journal
Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2020). Evaluation of the profiles of CB1 cannabinoid receptor signalling bias using joint kinetic modelling. British Journal of Pharmacology, 177, 3449-3463. doi: 10.1111/bph.15066
Finlay, D. B., Sircombe, K. J., Nimick, M., Jones, C., & Glass, M. (2020). Terpenoids from cannabis do not mediate an entourage effect by acting at cannabinoid receptors. Frontiers in Pharmacology, 11, 359. doi: 10.3389/fphar.2020.00359
Gamage, T. F., Barrus, D. A., Kevin, R. C., Finlay, D. B., Lefever, T. W., Patel, P. R., … Glass, M., … Thomas, B. F. (2020). In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018. Pharmacology Biochemistry & Behavior, 193, 172918. doi: 10.1016/j.pbb.2020.172918
Patel, M., Manning, J. J., Finlay, D. B., Javitch, J. A., Banister, S. D., Grimsey, N. L., & Glass, M. (2020). Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists. Biochemical Pharmacology, 175, 113871. doi: 10.1016/j.bcp.2020.113871
Ong, R. S., Kappatos, D. C., Russell, S. G. G., Poulsen, H. A., Banister, S. D., Gerona, R. R., Glass, M., … McCarthy, M.-J. (2020). Simultaneous analysis of 29 synthetic cannabinoids and metabolites, amphetamines and cannabinoids in human whole blood by liquid chromatography-tandem mass spectrometry: A New Zealand perspective of use in 2018. Drug Testing & Analysis, 12, 195-214. doi: 10.1002/dta.2697
Journal - Research Other
Finlay, D. B., Duffull, S. B., & Glass, M. (2020). 100 years of modelling ligand-receptor binding and response: A focus on GPCRs. British Journal of Pharmacology, 177, 1472-1484. doi: 10.1111/bph.14988
2019
Journal - Research Article
Saroz, Y., Kho, D. T., Glass, M., Graham, E. S., & Grimsey, N. L. (2019). Cannabinoid receptor 2 (CB2) signals via G-alpha-s and induces IL-6 and IL-10 cytokine secretion in human primary leukocytes. ACS Pharmacology & Translational Science, 2(6), 414-428. doi: 10.1021/acsptsci.9b00049
Finlay, D. B., Manning, J. J., Ibsen, M. S., Macdonald, C. E., Patel, M., Javitch, J. A., … Glass, M. (2019). Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity profiles? A case study of AMB-FUBINACA. ACS Chemical Neuroscience, 10, 4350-4360. doi: 10.1021/acschemneuro.9b00429
Kevin, R. C., Anderson, L., McGregor, I. S., Boyd, R., Manning, J. J., Glass, M., … Banister, S. D. (2019). CUMYL-4CN-BINACA is an efficacious and potent pro-convulsant synthetic cannabinoid receptor agonist. Frontiers in Pharmacology, 10, 595. doi: 10.3389/fphar.2019.00595
Banister, S. D., Adams, A., Kevin, R. C., Macdonald, C., Glass, M., Boyd, R., … Gerona, R. R. (2019). Synthesis and pharmacology of new psychoactive substance 5F‐CUMYL‐P7AICA, a scaffold-hopping analog of synthetic cannabinoid receptor agonists 5F‐CUMYL‐PICA and 5F‐CUMYL‐PINACA. Drug Testing & Analysis, 11(2), 279-291. doi: 10.1002/dta.2491
Ibsen, M. S., Finlay, D. B., Patel, M., Javtich, J. A., Glass, M., & Grimsey, N. L. (2019). Cannabinoid CB1 and CB2 receptor-mediated arrestin translocation: Species, subtype, and agonist-dependence. Frontiers in Pharmacology, 10, 350. doi: 10.3389/fphar.2019.00350
Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2019). Model-free and kinetic modelling approaches for characterising non-equilibrium pharmacological pathway activity: Internalisation of cannabinoid CB1 receptors. British Journal of Pharmacology, 176, 2593-2607. doi: 10.1111/bph.14684
Wiley, J. L., Lefever, T. W., Glass, M., & Thomas, B. F. (2019). Do you feel it now? Route of administration and Δ9-tetrahydrocannabinol-like discriminative stimulus effects of synthetic cannabinoids in mice. NeuroToxicology, 73, 161-167. doi: 10.1016/j.neuro.2019.04.002
Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2019). An intact model for quantifying functional selectivity. Scientific Reports, 9, 2557. doi: 10.1038/s41598-019-39000-z
Singh, S., Oyagawa, C. R. M., Macdonald, C., Grimsey, N. L., Glass, M., & Vernall, A. J. (2019). Chromenopyrazole-based high affinity, selective fluorescent ligands for cannabinoid type 2 receptor. ACS Medicinal Chemistry Letters, 10, 209-214. doi: 10.1021/acsmedchemlett.8b00597
Journal - Research Other
Grant, P. S., Kahlcke, N., Govindpani, K., Hunter, M., MacDonald, C., Brimble, M. A., Glass, M., & Furkert, D. P. (2019). Divalent cannabinoid-1 receptor ligands: A linker attachment point survey of SR141716A for development of high-affinity CB1R molecular probes. Bioorganic & Medicinal Chemistry Letters, 29(21), 126644. doi: 10.1016/j.bmcl.2019.126644
Glass, M., & Ashton, J. C. (2019). What is medicinal cannabis? New Zealand Medical Journal, 132(1494), 49-56. Retrieved from https://www.nzma.org.nz/journal
Banister, S. D., Arnold, J. C., Connor, M., Glass, M., & McGregor, I. S. (2019). Dark classics in chemical neuroscience: Δ9-tetrahydrocannabinol. ACS Chemical Neuroscience, 10, 2160-2175. doi: 10.1021/acschemneuro.8b00651
Conference Contribution - Published proceedings: Abstract
Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2019). An evaluation of timed snapshot signalling bias analyses for non-equilibrium systems. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Population Approach Group of Australia and New Zealand (PAGANZ) Joint Scientific Meeting: Shared Horizons: Optimizing Drug Response to Improve Patient Outcomes. (pp. 45). Retrieved from https://www.asceptasm.com
Saroz, Y., Kho, D. T., Glass, M., Graham, E. S., & Grimsey, N. L. (2019). Molecular pharmacology of cannabinoid receptor 2, a promising immunomodulatory target. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Population Approach Group of Australia and New Zealand (PAGANZ) Joint Scientific Meeting: Shared Horizons: Optimizing Drug Response to Improve Patient Outcomes. (pp. 58). Retrieved from https://www.asceptasm.com
Sachdev, S., Santiago, M., Patel, M., Manandhar, P., Udoh, M., Glass, M., & Connor, M. (2019). Investigation of the specificity of cannabidiol signalling. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Population Approach Group of Australia and New Zealand (PAGANZ) Joint Scientific Meeting: Shared Horizons: Optimizing Drug Response to Improve Patient Outcomes. (pp. 52). Retrieved from https://www.asceptasm.com
Glass, M., Oldfield, K., on behalf of the Medical Cannabis Research Collaborative (NZ). (2019). The pros and cons of the use of cannabis as a medicine in general practice: From the lab to the patient (and everything in between) [Workshop]. Proceedings of the Royal New Zealand College of General Practitioners (RNZCGP) Annual Conference. Retrieved from http://www.generalpractice.org.nz/gp19
Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2019). Evaluation of the fingerprint profiles of the cannabinoid-1 receptor signalling via a kinetic modelling approach. Proceedings of the 20th Annual Population Approach Group in Australia and New Zealand Meeting (PAGANZ). (pp. 43-44). Retrieved from https://www.paganz.org/auckland-2019
Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2019). A cohesive model framework of receptor pharmacology: Beyond the Emax model. Proceedings of the Twenty-Eighth Annual Meeting of the Population Approach Group in Europe (PAGE). (pp. 50-52). Retrieved from https://www.page-meeting.org
Conference Contribution - Poster Presentation (not in published proceedings)
Manning, J. J., Finlay, D. B., & Glass, M. (2019, August-September). G Protein-coupled receptor kinases enhance and inhibit recruitment of β-arrestins to the type-1 cannabinoid receptor. Poster session presented at the Queenstown Molecular Biology (QMB) Meetings, Queenstown, New Zealand.
Patel, M., Manning, J. J., Finlay, D. B., Banister, S. D., Grimsey, N. L., & Glass, M. (2019, August-September). Novel synthetic cannabinoids possess signalling profiles distinct from THC at the type 1 cannabinoid receptor. Poster session presented at the Queenstown Molecular Biology (QMB) Meetings, Queenstown, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Singh, S., Oyagawa, C. R. M., Grimsey, N. L., Tyndall, J. D. A., Glass, M., & Vernall, A. J. (2019, August-September). Chromenopyrazole-based chemical tools to study cannabinoid type 2 receptor. Verbal presentation at the Queenstown Molecular Biology (QMB) Meetings, Queenstown, New Zealand.
Finlay, D. B., Gamage, T. F., Patel, P. R., Thomas, B. F., Zhang, Y., & Glass, M. (2019, August-September). Towards neutral antagonism of the CB1 cannabinoid receptor. Verbal presentation at the Queenstown Molecular Biology (QMB) Meetings, Queenstown, New Zealand.
Saroz, Y., Kho, D. T., Glass, M., Graham, E. S., & Grimsey, N. L. (2019, August-September). Cannabinoid receptor 2 signalling bias and function in human primary immune cells. Verbal presentation at the Queenstown Molecular Biology (QMB) Meetings, Queenstown, New Zealand.
Glass, M., Boden, J., Potiki, T., & Lennox Thompson, B. (2019, July). Legalising cannabis: Will it be wise, or why did we? Hear what the experts think. Panel discussion at the University of Otago Winter Symposium Series, Christchurch, New Zealand.
2018
Journal - Research Article
Hosie, S., Malone, D. T., Liu, S., Glass, M., Adlard, P. A., Hannan, A. J., & Hill-Yardin, E. L. (2018). Altered amygdala excitation and CB1 receptor modulation of aggressive behavior in the neuroligin-3 R451C mouse model of autism. Frontiers in Cellular Neuroscience, 12, 234. doi: 10.3389/fncel.2018.00234
Cooper, A. G., Oyagawa, C. R. M., Manning, J. J., Singh, S., Hook, S., Grimsey, N. L., Glass, M., Tyndall, J. D. A., & Vernall, A. J. (2018). Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1,8-naphthyridin-2-(1H)-one-3-carboxamide scaffold. MedChemComm, 9(12), 2055-2067. doi: 10.1039/c8md00448j
Oyagawa, C. R. M., de la Harpe, S. M., Saroz, Y., Glass, M., Vernall, A. J., & Grimsey, N. L. (2018). Cannabinoid Receptor 2 signalling bias elicited by 2,4,6-trisubstituted 1,3,5-triazines. Frontiers in Pharmacology, 9, 1202. doi: 10.3389/fphar.2018.01202
Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2018). An evaluation of the operational model when applied to quantify functional selectivity. British Journal of Pharmacology, 175, 1654-1668. doi: 10.1111/bph.14171
Cooper, A. G., MacDonald, C., Glass, M., Hook, S., Tyndall, J. D. A., & Vernall, A. J. (2018). Alkyl indole-based cannabinoid type 2 receptor tools: Exploration of linker and fluorophore attachment. European Journal of Medicinal Chemistry, 145, 770-789. doi: 10.1016/j.ejmech.2017.11.076
Conference Contribution - Published proceedings: Abstract
Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2018). Kinetic modelling of ligand mediated internalisation. Proceedings of the 19th Annual Population Approach Group in Australia and New Zealand Meeting (PAGANZ). Retrieved from http://paganz.org
Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2018). Application of pharmacometrics to stimulus response models to describe signalling profiles of the cannabinoid-1 receptor. Proceedings of the Twenty-Seventh Annual Meeting of the Population Approach Group in Europe (PAGE). (pp. 239-241). Retrieved from http://www.page-meeting.org/
Conference Contribution - Verbal presentation and other Conference outputs
Manning, J. J., Saldana, S. L., Cunningham, C. W., & Glass, M. (2018, August). Evaluation of novel allosteric modulators of the type-1 cannabinoid receptor. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.
Finlay, D. B., Lefever, T. W., Thomas, B. F., Wiley, J. L., & Glass, M. (2018, August). Evidence for in vivo toxicity of synthetic cannabinoids in rodents. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.
Glass, M. (2018, August). An introduction to cannabis as a medicine. Invited presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.
Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2018, August). A kinetic model for describing signalling profiles of the cannabinoid-1 receptor. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.
Macdonald, C., Finlay, D., Joseph, W., Finlay, G., Graham, E. S., & Glass, M. (2018, August). Cannabinoid receptor expression and signalling in primary glioblastoma multiforme (GMB) cultures. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.
Glass, M., Finlay, D. B., Manning, J., MacDonald, C., & Bannister, S. (2018, August). Biased signalling of synthetic cannabinoids through CB1 receptors. Verbal presentation at the Queenstown Molecular Biology (QMB) Meetings, Queenstown, New Zealand.
2017
Chapter in Book - Research
Kho, D. T., Glass, M., & Graham, E. S. (2017). Is the cannabinoid CB2 receptor a major regulator of the neuroinflammatory axis of the neurovascular unit in humans? In D. Kendall & S. P. H. Alexander (Eds.), Advances in Pharmacology [Vol. 80: Cannabinoid pharmacology]. (pp. 207-221). Cambridge, MA: Academic Press. doi: 10.1016/bs.apha.2017.03.005
Cawston, E. E., Hunter, M. R., & Glass, M. (2017). Allosteric modulation of the cannabinoid CB1 receptor. In V. R. Preedy (Ed.), Handbook of cannabis and related pathologies: Biology, pharmacology, diagnosis, and treatment. (pp. 573-583). London, UK: Academic Press. doi: 10.1016/B978-0-12-800756-3.00070-3
Priestley, R., Glass, M., & Kendall, D. (2017). Functional selectivity at cannabinoid receptors. In D. Kendall & S. P. H. Alexander (Eds.), Advances in Pharmacology [Vol. 80: Cannabinoid pharmacology]. (pp. 207-221). Cambridge, MA: Academic Press. doi: 10.1016/bs.apha.2017.03.005
Hunter, M. R., Finlay, D. B., Macdonald, C. E., Cawston, E. E., Grimsey, N. L., & Glass, M. (2017). Real-time measurement of cannabinoid receptor-mediated cAMP signaling. In P. H. Reggio (Ed.), Methods in enzymology: Cannabinoids and their receptors (Vol. 593). (pp. 43-59). Cambridge, MA: Academic Press. doi: 10.1016/bs.mie.2017.05.001
Hunter, M. R., Finlay, D. B., & Glass, M. (2017). Signal transduction and regulation of the cannabinoid CB1 receptor. In V. R. Preedy (Ed.), Handbook of cannabis and related pathologies: Biology, pharmacology, diagnosis, and treatment. (pp. 563-572). London, UK: Academic Press. doi: 10.1016/B978-0-12-800756-3.00069-7
Ashton, J. C., Dowie, M. J., & Glass, M. (2017). The endocannabinoid system and human brain functions: Insight from memory, motor, and mood pathologies. In E. Murillo-Rodríguez (Ed.), The endocannabinoid system. (pp. 115-186). London, UK: Academic Press. doi: 10.1016/B978-0-12-809666-6.00005-8
Journal - Research Article
Finlay, D. B., Cawston, E. E., Grimsey, N. L., Hunter, M. R., Korde, A., Vemuri, V. K., … Glass, M. (2017). Gαs signalling of the CB1 receptor and the influence of receptor number. British Journal of Pharmacology, 174(15), 2545-2562. doi: 10.1111/bph.13866
Soethoudt, M., Grether, U., Fingerle, J., Grim, T. W., Fezza, F., de Petrocellis, L., … Finlay, D., … Glass, M., & van der Stelt, M. (2017). Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. Nature Communications, 8, 13958. doi: 10.1038/ncomms13958
Conference Contribution - Published proceedings: Abstract
Finlay, D. B., Zhu, X., Duffull, S. B., & Glass, M. (2017). Interpreting GPCR functional selectivity: A CB1 cannabinoid receptor case study. Proceedings of the Carolina Cannabinoid Collaborative Conference. (pp. 18). Retrieved from https://www.rti.org/event/carolina-cannabinoid-collaborative-2017-annual-conference
Glass, M., Finlay, D., Manning, J., Ibsen, M., & Grimsey, N. (2017). The role of arrestins in regulation of CB1 function, and implications of high-efficacy arrestin recruitement by toxic synthetic cannabinoids. Proceedings of the Carolina Cannabinoid Collaborative Conference. (pp. 9-10). Retrieved from https://www.rti.org/event/carolina-cannabinoid-collaborative-2017-annual-conference
Conference Contribution - Poster Presentation (not in published proceedings)
Cooper, A., Macdonald, C., Manning, J., Glass, M., Hook, S., Tyndall, J., & Vernall, A. (2017, September). Design, synthesis and pharmacological evaluation of fluorescent ligands as tools for studying cannabinoid type 2 receptor. Poster session presented at the 19th RSC/SCI Medicinal Chemistry Symposium, Cambridge, UK.
Conference Contribution - Verbal presentation and other Conference outputs
Oyagawa, C. R. M., de la Harpe, S., Woodhouse, B. J., Glass, M., Vernall, A. J., & Grimsey, N. L. (2017, September). Utilising novel ligands to investigate an unusual trafficking phenotype: Agonist-induced surface upregulation of cannabinoid receptor 2. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.
Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2017, September). An intact model framework for quantifying functional selectivity. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.
Finlay, D. B., Zhu, X., Duffull, S. B., & Glass, M. (2017, September). Occupancy-efficacy interactions and the interpretation of functional selectivity: A CB1 cannabinoid receptor case study. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.
2016
Journal - Research Article
Longworth, M., Banister, S. D., Mack, J. B. C., Glass, M., Connor, M., & Kassiou, M. (2016). The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities. Forensic Toxicology, 34(2), 286-303. doi: 10.1007/s11419-016-0316-y
Hunter, M. R., Grimsey, N. L., & Glass, M. (2016). Sulfation of the FLAG epitope is affected by co-expression of G protein-coupled receptors in a mammalian cell model. Scientific Reports, 6, 27316. doi: 10.1038/srep27316
Redmond, W. J., Cawston, E. E., Grimsey, N. L., Stuart, J., Edington, A. R., Glass, M., & Connor, M. (2016). Identification of N‐arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors. British Journal of Pharmacology, 173(1), 115-127. doi: 10.1111/bph.13341
Banister, S. D., Longworth, M., Kevin, R., Sachdev, S., Santiago, M., Stuart, J., … Glass, M., … Kassiou, M. (2016). Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues. ACS Chemical Neuroscience, 7(9), 1241-1254. doi: 10.1021/acschemneuro.6b00137
Finlay, D. B., Joseph, W. R., Grimsey, N. L., & Glass, M. (2016). GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-arachidonoyl glycine. PeerJ, 2016(4), e1835. doi: 10.7717/peerj.1835
Journal - Research Other
Glass, M., Govindpani, K., Furkert, D. P., Hurst, D. P., Reggio, P. H., & Flanagan, J. U. (2016). One for the price of two: Are bivalent ligands targeting cannabinoid receptor dimers capable of simultaneously binding to both receptors? Trends in Pharmacological Sciences, 37(5), 353-363. doi: 10.1016/j.tips.2016.01.010
Conference Contribution - Published proceedings: Abstract
Finlay, D. B., Hunter, M. R., Grimsey, N. L., Vemuri, V. K., Makriyannis, A., & Glass, M. (2016). GS coupling of CB1: Ligand bias and the influence of receptor number. Proceedings of the 26th Annual Symposium of the International Cannabinoid Research Society. (pp. P1-22). Research Triangle Park, NC: International Cannabinoid Research Society. Retrieved from http://icrs.co
Cooper, A. G., Macdonald, C., Glass, M., Hook, S., Tyndall, J. D. A., & Vernall, A. J. (2016). Development of tools for studying cannabinoid type 2 receptor: Design, synthesis and pharmacological evaluation of fluorescent ligands and intermediates. Proceedings of the Diagnostics, Drugs, Devices, Discovery (D4) Conference. Retrieved from http://www.otago.ac.nz/d4/index.html
Cooper, A. G., Macdonald, C., Glass, M., Hook, S., Tyndall, J. D. A., & Vernall, A. J. (2016). Development of fluorescent ligands as tools for studying cannabinoid type 2 receptor. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists and the Molecular Pharmacology of G Protein-Coupled Receptors (ASCEPT-MPGPCR) Joint Scientific Meeting. 709. Retrieved from http://www.asceptasm.com/
Conference Contribution - Poster Presentation (not in published proceedings)
Cooper, A. G., Macdonald, C., Glass, M., Hook, S., Tyndall, J. D. A., & Vernall, A. J. (2016, August-September). Development of fluorescent ligands as tools for studying cannabinoid type 2 receptor. Poster session presented at the European Federation for Medicinal Chemistry (EFMC) International Symposium on Medicinal Chemistry, Manchester, UK.
2015
Journal - Research Article
Banister, S. D., Stuart, J., Conroy, T., Longworth, M., Manohar, M., Beinat, C., … Glass, M., … Kassiou, M. (2015). Structure–activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues. Forensic Toxicology, 33(2), 355-366. doi: 10.1007/s11419-015-0282-9
Banister, S. D., Moir, M., Stuart, J., Kevin, R. C., Wood, K. E., Longworth, M., … Glass, M., … Kassiou, M. (2015). Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chemical Neuroscience, 6(9), 1546-1559. doi: 10.1021/acschemneuro.5b00112
Banister, S. D., Stuart, J., Kevin, R. C., Edington, A., Longworth, M., Wilkinson, S. M., … Glass, M., … Kassiou, M. (2015). Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chemical Neuroscience, 6(8), 1445-1458. doi: 10.1021/acschemneuro.5b00107
Cawston, E. E., Connor, M., Di Marzo, V., Silvestri, R., & Glass, M. (2015). Distinct temporal fingerprint for cyclic adenosine monophosphate (cAMP) signaling of indole-2-carboxamides as allosteric modulators of the cannabinoid receptors. Journal of Medicinal Chemistry, 58(15), 5979-5988. doi: 10.1021/acs.jmedchem.5b00579
Khajehali, E., Malone, D. T., Glass, M., Sexton, P. M., & Christopoulos, A. (2015). Biased agonism and biased allosteric modulation at the CB1 cannabinoid receptor. Molecular Pharmacology, 88(2), 368-379. doi: 10.1124/mol.115.099192
Journal - Research Other
Hunter, M. R., & Glass, M. (2015). Increasing the flexibility of the LANCE cAMP detection kit [Brief communication]. Journal of Pharmacological & Toxicological Methods, 71, 42-45. doi: 10.1016/j.vascn.2014.10.008
2014
Journal - Research Article
Young, D., Fong, D. M., Lawlor, P. A., Wu, A., Mouravlev, A., McRae, M., Glass, M., … During, M. J. (2014). Adenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy. Gene Therapy, 21(12), 1029-1040. doi: 10.1038/gt.2014.82
Yee, A. G., Lee, S.-M., Hunter, M. R., Glass, M., Freestone, P. S., & Lipski, J. (2014). Effects of the Parkinsonian toxin MPP+ on electrophysiological properties of nigral dopaminergic neurons. NeuroToxicology, 45, 1-11. doi: 10.1016/j.neuro.2014.08.009
Dowie, M. J., Grimsey, N. L., Hoffman, T., Faull, R. L. M., & Glass, M. (2014). Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington's disease brain. Journal of Chemical Neuroanatomy, 59-60, 62-71. doi: 10.1016/j.jchemneu.2014.06.004
MacDonald, C., Finlay, D. B., Jabed, A., Glass, M., & Graham, E. S. (2014). Development of positive control tissue for in situ hybridisation using Alvetex scaffolds. Journal of Neuroscience Methods, 238, 70-77. doi: 10.1016/j.jneumeth.2014.09.006
Conference Contribution - Published proceedings: Abstract
van Kralingen, C., Finlay, D., Glass, M., & Graham, E. S. (2014). Assessment of CB2 in human brain tissue using in situ hybridisation. Proceedings of the 24th Annual Symposium of the International Cannabinoid Research Society. (pp. P3-22). Retrieved from http://icrs.co
2013
Journal - Research Article
Banister, S. D., Wilkinson, S. M., Longworth, M., Stuart, J., Apetz, N., English, K., … Glass, M., … Kassiou, M. (2013). The synthesis and pharmacological evaluation of adamantane-derived indoles: Cannabimimetic drugs of abuse. ACS Chemical Neuroscience, 4(7), 1081-1092. doi: 10.1021/cn400035r
Cawston, E. E., Redmond, W. J., Breen, C. M., Grimsey, N. L., Connor, M., & Glass, M. (2013). Real-time characterization of cannabinoid receptor 1 (CB1) allosteric modulators reveals novel mechanism of action. British Journal of Pharmacology, 170(4), 893-907. doi: 10.1111/bph.12329
Graham, E. S., Woo, K. K., Aalderink, M., Fry, S., Greenwood, J. M., Glass, M., & Dragunow, M. (2013). M1 muscarinic receptor activation mediates cell death in M1-HEK293 cells. PLoS ONE, 8(9), e72011. doi: 10.1371/journal.pone.0072011
2012
Journal - Research Article
Grimsey, N. L., Moodley, K. S., Glass, M., & Graham, E. S. (2012). Sensitive and accurate quantification of human leukocyte migration using high-content discovery-1 imaging system and ATPlite assay. Journal of Biomolecular Screening, 17(3), 386-393. doi: 10.1177/1087057111428985
Horváth, B., Magid, L., Mukhopadhyay, P., Bátkai, S., Rajesh, M., Park, O., … Glass, M., … Pacher, P. (2012). A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury. British Journal of Pharmacology, 165(8), 2462-2478. doi: 10.1111/j.1476-5381.2011.01381.x
2011
Journal - Research Article
Grimsey, N. L., Goodfellow, C. E., Dragunow, M., & Glass, M. (2011). Cannabinoid receptor 2 undergoes Rab5-mediated internalization and recycles via a Rab11-dependent pathway. Biochimica et Biophysica Acta: Molecular Cell Research, 1813(8), 1554-1560. doi: 10.1016/j.bbamcr.2011.05.010
Moodley, K., Angel, C. E., & Glass, M. (2011). Real-time profiling of NK cell killing of human astrocytes using xCELLigence technology. Journal of Neuroscience Methods, 200(2), 173-180. doi: 10.1016/j.jneumeth.2011.07.005
Goodfellow, C. E., Graham, S. E., Dragunow, M., & Glass, M. (2011). Characterization of NTera2/D1 cells as a model system for the investigation of cannabinoid function in human neurons and astrocytes. Journal of Neuroscience Research, 89(10), 1685-1697. doi: 10.1002/jnr.22692
Conference Contribution - Published proceedings: Abstract
Ashton, J. C., Brownjohn, P. W., Rivers, J. R., Mackie, K., Dowie, M., & Glass, M. (2011). The cannabinoid CB2 receptor controversy: A receptor with an identity crisis. In B. Leitch (Ed.), Proceedings of the 29th International Australasian Winter Conference on Brain Research. 29, 8.4. AWCBR. Retrieved from http://psy.otago.ac.nz/awcbr/abstracts/abstracts2011.html
2010
Journal - Research Article
Grimsey, N. L., Graham, E. S., Dragunow, M., & Glass, M. (2010). Cannabinoid Receptor 1 trafficking and the role of the intracellular pool: Implications for therapeutics. Biochemical Pharmacology, 80(7), 1050-1062. doi: 10.1016/j.bcp.2010.06.007
Dowie, M. J., Howard, M. L., Nicholson, L. F. B., Faull, R. L. M., Hannan, A. J., & Glass, M. (2010). Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice. Neuroscience, 170(1), 324-336. doi: 10.1016/j.neuroscience.2010.06.056
Dowie, M. J., Scotter, E. L., Molinari, E., & Glass, M. (2010). The therapeutic potential of G-protein coupled receptors in Huntington's disease. Pharmacology & Therapeutics, 128(2), 305-323. doi: 10.1016/j.pharmthera.2010.07.008
Scotter, E. L., Goodfellow, C. E., Graham, E. S., Dragunow, M., & Glass, M. (2010). Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease. British Journal of Pharmacology, 160(3), 747-761. doi: 10.1111/j.1476-5381.2010.00773.x
Scotter, E. L., Abood, M. E., & Glass, M. (2010). The endocannabinoid system as a target for the treatment of neurodegenerative disease. British Journal of Pharmacology, 160(3), 480-498. doi: 10.1111/j.1476-5381.2010.00735.x
Graham, E. S., Angel, C. E., Schwarcz, L. E., Dunbar, P. R., & Glass, M. (2010). Detailed characterisation of CB2 receptor protein expression in peripheral blood immune cells from healthy human volunteers using flow cytometry. International Journal of Immunopathology & Pharmacology, 23(1), 25-34. doi: 10.1177/039463201002300103
2009
Chapter in Book - Research
Goodfellow, C. E., & Glass, M. (2009). Anandamide receptor signal transduction. In G. Litwack (Ed.), Vitamins and hormones. (pp. 79-110). London, UK: Academic Press. doi: 10.1016/S0083-6729(09)81004-2
Journal - Research Article
Allen, K. L., Waldvogel, H. J., Glass, M., & Faull, R. L. M. (2009). Cannabinoid (CB1), GABAA and GABAB receptor subunit changes in the globus pallidus in Huntington's disease. Journal of Chemical Neuroanatomy, 37(4), 266-281. doi: 10.1016/j.jchemneu.2009.02.001
Dowie, M. J., Bradshaw, H. B., Howard, M. L., Nicholson, L. F. B., Faull, R. L. M., Hannan, A. J., & Glass, M. (2009). Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. Neuroscience, 163(1), 456-465. doi: 10.1016/j.neuroscience.2009.06.014
Graham, E. S., Ashton, J. C., & Glass, M. (2009). Cannabinoid receptors: A brief history and 'What's hot'. Frontiers in Bioscience, 14, 944-957. doi: 10.2741/3288
2008
Chapter in Book - Research
Ashton, J. C., & Glass, M. (2008). Multiple roles for cannabinoids in neuroprotection during oxidative stress injury. In O. M. Roux (Ed.), Brain hypoxia-ischemia research progress. (pp. 229-244). New York: Nova.
Journal - Research Article
Mitchell, M. D., Sato, T. A., Wang, A., Keelan, J. A., Ponnampalam, A. P., & Glass, M. (2008). Cannabinoids stimulate prostaglandin production by human gestational tissues through a tissue- and CB1-receptor-specific mechanism. American Journal of Physiology: Endocrinology & Metabolism, 294(2), E352-E356. doi: 10.1152/ajpendo.00495.2007
Grimsey, N. L., Goodfellow, C. E., Scotter, E. L., Dowie, M. J., Glass, M., & Graham, E. S. (2008). Specific detection of CB1 receptors: Cannabinoid CB1 receptor antibodies are not all created equal! Journal of Neuroscience Methods, 171(1), 78-86. doi: 10.1016/j.jneumeth.2008.02.014
Chamley, L. W., Bhalla, A., Stone, P. R., Liddell, H., O’Carroll, S., Kearn, C., & Glass, M. (2008). Nuclear localisation of the endocannabinoid metabolizing enzyme fatty acid amide hydrolase (FAAH) in invasive trophoblasts and an association with recurrent miscarriage. Placenta, 29(11), 970-975. doi: 10.1016/j.placenta.2008.08.003
Scotter, E. L., Narayan, P., Glass, M., & Dragunow, M. (2008). High throughput quantification of mutant huntingtin aggregates. Journal of Neuroscience Methods, 171(1), 174-179. doi: 10.1016/j.jneumeth.2008.02.007
Conference Contribution - Published proceedings: Full paper
Grimsey, N. L., Narayan, P. J., Dragunow, M., & Glass, M. (2008). A novel high-throughput assay for the quantitative assessment of receptor trafficking. Clinical & Experimental Pharmacology & Physiology, 35(11), (pp. 1377-1382). doi: 10.1111/j.1440-1681.2008.04991.x
Conference Contribution - Published proceedings: Abstract
Rivers, J. R., Sutherland, B. A., Brownjohn, P. W., Glass, M., & Ashton, J. C. (2008). Preliminary investigations into the specificity of antibody probes raised against the cannabinoid CBII receptor. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting. ASCEPT. Retrieved from http://phal.otago.ac.nz/ascept_docos/programme%202008.pdf
2007
Journal - Research Article
McPartland, J. M., Glass, M., Matias, I., Norris, R. W., & Kilpatrick, C. W. (2007). A shifted repertoire of endocannabinoid genes in the zebrafish (Danio rerio). Molecular Genetics & Genomics, 277(5), 555-570. doi: 10.1007/s00438-007-0207-3
McPartland, J. M., Glass, M., & Pertwee, R. B. (2007). Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: Interspecies differences. British Journal of Pharmacology, 152(5), 583-593. doi: 10.1038/sj.bjp.0707399
Ashton, J. C., & Glass, M. (2007). The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Current Neuropharmacology, 5(2), 73-80.
Ashton, J. C., Rahman, R. M. A., Nair, S. M., Sutherland, B. A., Glass, M., & Appleton, I. (2007). Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neuroscience Letters, 412, 114-117.
2006
Journal - Research Article
McPartland, J. M., Agraval, J., Gleeson, D., Heasman, K., & Glass, M. (2006). Cannabinoid receptors in invertebrates. Journal of Evolutionary Biology, 19(2), 366-373. doi: 10.1111/j.1420-9101.2005.01028.x
Curtis, M. A., Faull, R. L. M., & Glass, M. (2006). A novel population of progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and Huntington's disease human brain. Journal of Chemical Neuroanatomy, 31(3), 210-215. doi: 10.1016/j.jchemneu.2006.01.005
Graham, E. S., Ball, N., Scotter, E. L., Narayan, P., Dragunow, M., & Glass, M. (2006). Induction of Krox-24 by endogenous cannabinoid type 1 receptors in Neuro2a cells is mediated by the MEK-ERK MAPK pathway and is suppressed by the phosphatidylinositol 3-kinase pathway. Journal of Biological Chemistry, 281(39), 29085-29095. doi: 10.1074/jbc.M602516200
McPartland, J. M., Matias, I., Di Marzo, V., & Glass, M. (2006). Evolutionary origins of the endocannabinoid system. Gene, 370(1-2), 64-74. doi: 10.1016/j.gene.2005.11.004
Saidak, Z., Blake-Palmer, K., Hay, D. L., Northup, J. K., & Glass, M. (2006). Differential activation of G-proteins by μ-opioid receptor agonists. British Journal of Pharmacology, 147(6), 671-680. doi: 10.1038/sj.bjp.0706661
Conference Contribution - Published proceedings: Abstract
Ashton, J. C., Glass, M., Sutherland, B., Rahman, R., & Appleton, I. (2006). Induction of cannabinoid cb2 receptor positive cells in the brain by stroke. Journal of Neurochemistry. 98(Suppl. 1), (pp. 65-66). [Abstract]
2005
Journal - Research Article
Kearn, C. S., Blake-Palmer, K., Daniel, E., Mackie, K., & Glass, M. (2005). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: A mechanism for receptor cross-talk? Molecular Pharmacology, 67(5), 1697-1704. doi: 10.1124/mol.104.006882
Journal - Research Other
Glass, M., Hong, J., Sato, T. A., & Mitchell, M. D. (2005). Misidentification of prostamides as prostaglandins [Rapid communication]. Journal of Lipid Research, 46(7), 1364-1368. doi: 10.1194/jlr.C500006-JLR200
2004
Journal - Research Article
Park, B., McPartland, J. M., & Glass, M. (2004). Cannabis, cannabinoids and reproduction. Prostaglandins, Leukotrienes & Essential Fatty Acids, 70(2), 189-197. doi: 10.1016/j.plefa.2003.04.007
Helliwell, R. J. A., Chamley, L. W., Blake-Palmer, K., Mitchell, M. D., Wu, J., Kearn, C. S., & Glass, M. (2004). Characterization of the endocannabinoid system in early human pregnancy. Journal of Clinical Endocrinology & Metabolism, 89(10), 5168-5174. doi: 10.1210/jc.2004-0388
Glass, M., van Dellen, A., Blakemore, C., Hannan, A. J., & Faull, R. L. M. (2004). Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience, 123(1), 207-212. doi: 10.1016/S0306-4522(03)00595-5
2003
Journal - Research Article
Park, B., Gibbons, H. M., Mitchell, M. D., & Glass, M. (2003). Identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta. Placenta, 24(10), 990-995. doi: 10.1016/S0143-4004(03)00165-6
McPartland, J. M., & Glass, M. (2003). Functional mapping of cannabinoid receptor homologs in mammals, other vertebrates, and invertebrates. Gene, 312(1-2), 297-303. doi: 10.1016/S0378-1119(03)00638-3
2002
Journal - Research Article
McAllister, S. D., & Glass, M. (2002). CB1 and CB2 receptor-mediated signalling: A focus on endocannabinoids. Prostaglandins, Leukotrienes & Essential Fatty Acids, 66(2-3), 161-171. doi: 10.1054/plef.2001.0344
2001
Journal - Research Article
McPartland, J., Di Marzo, V., De Petrocellis, L., Mercer, A., & Glass, M. (2001). Cannabinoid receptors are absent in insects. Journal of Comparative Neurology, 436(4), 423-429. doi: 10.1002/cne.1078
Glass, M. (2001). The role of cannabinoids in neurodegenerative diseases. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 25(4), 743-765. doi: 10.1016/S0278-5846(01)00162-2
McPartland, J., Di Marzo, V., De Petrocellis, L., Mercer, A. R., & Glass, M. (2001). Cannabinoid receptors absent in insects. Journal of Comparative Neurology, 436, 423-429.
Journal - Research Other
McPartland, J. M., & Glass, M. (2001). Nematicidal effects of hemp (Cannabis sativa) may not be mediated by cannabinoid receptors. New Zealand Journal of Crop & Horticultural Science, 29(4), 301-307. doi: 10.1080/01140671.2001.9514191
2000
Journal - Research Article
Glass, M., Dragunow, M., & Faull, R. L. M. (2000). The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience, 97(3), 505-519. doi: 10.1016/S0306-4522(00)00008-7
Buckley, N. E., McCoy, K. L., Mezey, É., Bonner, T., Zimmer, A., Felder, C. C., & Glass, M. (2000). Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor. European Journal of Pharmacology, 396(2-3), 141-149. doi: 10.1016/S0014-2999(00)00211-9
1999
Journal - Research Article
Glass, M., & Northup, J. K. (1999). Agonist selective regulation of G proteins by cannabinoid CB1 and CB2 receptors. Molecular Pharmacology, 56(6), 1362-1369. doi: 10.1124/mol.56.6.1362
1998
Journal - Research Article
Felder, C. C., & Glass, M. (1998). Cannabinoid receptors and their endogenous agonists. Annual Review of Pharmacology & Toxicology, 38, 179-200.
Felder, C. C., Joyce, K. E., Briley, E. M., Glass, M., Mackie, K. P., Fahey, K. J., … Brownstein, M. (1998). LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. Journal of Pharmacology & Drug Metabolism, 284(1), 291-297.
1997
Journal - Research Article
Glass, M., Dragunow, M., & Faull, R. L. M. (1997). Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 77(2), 299-318. doi: 10.1016/S0306-4522(96)00428-9
Glass, M., & Felder, C. C. (1997). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs linkage to the CB1 receptor. Journal of Neuroscience, 17(14), 5327-5333. doi: 10.1523/JNEUROSCI.17-14-05327.1997
Journal - Research Other
Glass, M., Brotchie, J. M., & Maneuf, Y. P. (1997). Modulation of neurotransmission by cannabinoids in the basal ganglia. European Journal of Neuroscience, 9(2), 199-203. doi: 10.1111/j.1460-9568.1997.tb01390.x
1996
Journal - Research Article
Glass, M., Faull, R. L. M., Bullock, J. Y., Jansen, K., Mee, E. W., Walker, E. B., … Dragunow, M. (1996). Loss of A1 adenosine receptors in human temporal lobe epilepsy. Brain Research, 710(1-2), 56-68. doi: 10.1016/0006-8993(95)01313-X
1995
Journal - Research Article
Glass, M., & Dragunow, M. (1995). Induction of the Krox 24 transcription factor in striosomes by a cannabinoid agonist. NeuroReport, 6(2), 241-244.
Glass, M., & Dragunow, M. (1995). Neurochemical and morphological changes associated with human epilepsy. Brain Research Reviews, 21(1), 29-41. doi: 10.1016/0165-0173(95)00005-N
1994
Journal - Research Article
Dragunow, M., Tse, C., Glass, M., & Lawlor, P. (1994). c-fos antisense reduces expression of Krox 24 in rat caudate and neocortex. Cellular & Molecular Neurobiology, 14(5), 395-405.
1993
Journal - Research Article
Glass, M., Faull, R. L. M., & Dragunow, M. (1993). Localisation of the adenosine uptake site in the human brain: A comparison with the distribution of adenosine A1 receptors. Brain Research, 710(1-2), 79-91. doi: 10.1016/0006-8993(95)01318-0
Glass, M., Faull, R. L. M., & Dragunow, M. (1993). Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience, 56(3), 523-527. doi: 10.1016/0306-4522(93)90352-G